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Abstract. The potential of circulating tumor cells (CTCs) in
the diagnosis and prognosis of cancer patients has become
increasingly attractive. However, molecular analysis of CTCs
is hindered by low sensitivity and a high level of background
leukocytes in CTC enrichment technologies. We have developed a novel protocol using a microfluidic device, which
enriches and retrieves CTCs from blood samples. The principle of CTC capturing is that tumor cells are larger and less
deformable than normal blood cells. To evaluate the potential
of utilizing Celsee PREP100 in CTC molecular analysis, we
prepared prostate cancer cell lines PC3 and LNCaP, retrieved
the captured cells and analyzed them using PCR amplicon
sequencing. We were able to recover an average of 79% of
110‑1,100 PC3 and 60‑1,500 LNCaP cells, and detect the
p.K139fs*3 deletion of the p53 gene in PC3 cells and p.T877A
mutation of the androgen receptor gene in LNCaP cells.
Next, we spiked these two types of cells into normal donor
blood samples, captured the cells and analyzed them using
PCR amplicon sequencing. The PC3 and LNCaP cells were
captured and retrieved with the ratio of captured CTCs to the
background leukocytes reaching 1:1.5 for PC3 and 1:2.9 for
LNCaP cells. We further revealed that the p.K139fs*3 deletion
and p.T877A mutation can be detected in the captured PC3
and LNCaP cells, respectively. We successfully validated
this approach using clinical blood samples from patients with
metastatic prostate cancer. Our results demonstrated a novel
approach for CTC enrichment and illustrated the potential of
CTC molecular characterization for diagnosis, prognosis and
treatment selection of patients with metastatic malignancy.
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Introduction
Circulating tumor cells (CTCs) have been identified in the
blood and bone marrow of patients with breast, prostate and
colon cancers (1‑3) in as low as 1/100 million or 1 billion
blood cells. Molecular characterization of CTCs may
provide a greater understanding of the disease metastases,
identify aggressive tumors and enable therapeutic selection
and monitoring of the disease for patients undergoing treatment (4,5). A variety of technologies have been developed
to improve detection and capture of CTCs from peripheral
blood, which include immune‑magnetic bead separation using
monoclonal antibodies targeting cell‑surface antigens for positive or negative selection, cell sorting using flow cytometry,
filtration‑based size separation, density gradient centrifugation, microfluidic devices and fast‑scan imaging (6‑10). For
example, CellSearch™ was the first CTC technology that
demonstrated its clinical validity in predicting progression‑free
and overall survival of metastatic cancer patients based on
CTC enumeration (3‑6).
It is of great interest to go beyond cell enumeration and
further characterize the CTCs by assessing clinically relevant
molecular markers on or within CTCs to gain insight into the
mechanisms of metastasis and best treatment modalities for
patients (1‑3,11,12). For example, significant progress has been
made in breast cancer, including effective hormonal therapy,
chemotherapy and targeted therapies against estrogen receptor
(ER) and HER‑2. In prostate cancer, androgen receptor (AR)
variant 7 has been implicated in predicting response to targeted
therapies on AR. Established clinical, pathological features
and biomarker status are routinely used to guide treatment
options. It has become critically important to determine which
patients are most likely to beneﬁt from specific therapies.
Detecting such molecular markers using a minimally‑invasive
blood test for CTCs has great potential in clinical practice to
guide therapy choice for patients. However, despite advances
in CTC technologies, the low frequency of CTCs in cancer
patients and the extensive background leukocytes have limited
the synergism of biomarkers and CTC technologies (11,12).
We have developed a novel microf luidic device,
Celsee PREP100 that uses a size and deformability‑based
capturing mechanism of CTCs (13). The microfluidic chip
has a parallel network of fluidic channels which contain about
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56,000 capture chambers (13,14). The chip fabrication begins
with a silicon master device containing micro‑features that
make up a fluidic network (75‑µm deep), leading to individual
cell trapping chambers (20x25x30 µm) with a pore size of
10x8 µm. Each chamber ensures smaller blood cells such as
red blood cells and most of the leukocytes escape while larger
cancer cells get trapped and isolated in the chamber. The manufacturing process uses standard photo‑lithography and deep
reactive ion etching for micro‑fabrication. From the master
device, a soft elastomeric negative mold is created by pouring
and curing against the silicon master. The final micro‑substrate
is created by hot embossing a plastic plate made of cyclic olefin
polymer (COP) against the elastomeric negative mold. A thin
plastic laminate containing pressure‑sensitive adhesive is then
laminated against the COP micro‑substrate to create the final
microfluidic chip. The chip is placed on the Celsee PREP100
device for CTC capturing.
Since the device captures cells using a label‑free mechanism, it provides an improved sensitivity in capturing CTCs and
an open platform for investigators to use a variety of antibodies
to identify and characterize CTCs upon capturing (13,14). In
a previous study, we compared CTC enumeration between
the Celsee system and the FDA‑cleared CellSearch system
using blood samples from patients with metastatic prostate
cancer. CTC counts were significantly higher using the Celsee
system (14). The captured CTCs could also be retrieved reproducibly using a back‑flow procedure from the microfluidic chip
for further nucleic acid extraction and molecular analysis. In
the present study, we report the development of a novel protocol
for capturing cells using blood sample retrieval and analysis of
the cells using PCR amplicon sequencing. Using this method,
we evaluated the potential of applying Celsee PREP100 in
CTC molecular analysis by analyzing p.K139fs*3 of TP53
and p.T877A of AR in captured prostate cancer cell lines PC3
and LNCaP and in captured spiked‑in cells in normal donor
blood. The method was also tested successfully in clinical
blood samples from 11 patients with metastatic prostate
cancer successfully. Our results demonstrated the potential of
utilizing CTCs for diagnosis, prognosis and treatment selection of patients with metastatic malignancy.
Materials and methods
Materials. Prostate cancer cell lines PC3 and LNCaP were
purchased from the American Type Culture Collection (ATCC;
Manassas, VA, USA) and cultured in Dulbecco's modified
Eagle's medium (DMEM) containing 5% fetal bovine serum
(FBS) in a humidified incubator supplemented with 5% CO2.
Upon confluency, cells were digested with 0.5% trypsin and
passaged at a 1:4 ratio. Some cells were resuspended in culture
medium, counted and used for experiments. Blood samples
were obtained from healthy donors. Clinical blood samples
from patients with metastatic prostate cancer were obtained
at Henry Ford Health System (Detroit, MI, USA). The present
study was approved by the Institutional Review Board (IRB)
of the Henry Ford Health System and written consent was
obtained from all patients. Following informed consent, blood
samples from patients were acquired in 10 ml BCT Cell‑Free
DNA tubes (Streck, La Vista, NE, USA) or EDTA‑coated
Vacutainer® tubes (BD Biosciences, Franklin Lakes, NJ, USA).

Removal of CD45‑positive cells from blood samples and
CTC enrichment and staining. To test CTC enrichment
efficiency using the Celsee PREP100 instrument, 250 PC3
and 50 LNCaP cells were spiked into 4 ml of blood from
healthy donors. CD45‑positive cells were removed using
the RosetteSep Human CD45 Depletion Cocktail (Stemcell
Technologies, Inc., Cambridge, MA, USA) following
the manufacturer's protocol. The upper layer of plasma
cells was collected and added into the inlet funnel of the
Celsee PREP100. Cells were enriched in the microfluidic chip
and stained for cytokeratins, CD45 and nuclei using anti‑Pan
cytokeratin antibody (1:100 dilution; cat. no. 914204),
anti‑CD45 antibody (1:100 dilution; cat. no. 368515; both
antibodies were from BioLegend, Inc., San Diego, CA, USA)
and DAPI, using Celsee PREP100 CTC Immunochemistry
kit (Celsee Diagnostics, Plymouth, MI, USA). Cells enriched
on the slides were counted using the Celsee Analyzer (14).
Cytokeratins and DAPI‑positive and CD45‑negative cells
were counted as CTC cells. The enrichment efficiency was
calculated as the percentage of the enriched cells of the total
spiked‑in cells.
Cell retrieval using the Celsee PREP100 instrument. A
different amount of PC3 and LNCaP cells were spiked into
the priming buffer and retrieved in 2 ml phosphate‑buffered saline (PBS) using the Celsee PREP100 instrument
(Celsee Diagnostics) following the protocol provided by the
manufacturer. The cells were then concentrated in 10‑50 µl
by centrifugation at 500 x g for 10 min, and counted using
a hemocytometer. The retrieval efficiency was calculated as
the percentage of the retrieved cells of the total spiked‑in
cells.
Retrieval of spiked‑in PC3 and LNCaP cells in normal
donor blood samples. A different amount of PC3 and LNCaP
cells were spiked into 4 ml of blood from healthy donors.
After removal of the CD45‑positive cells and enrichment
of the spiked‑in CTCs as aforementioned, cells enriched in
the microfluidic chip were retrieved in 2 ml PBS using the
Celsee PREP100 instrument (Celsee Diagnostics) following
the manufacturer's protocol. These cells were then collected
by centrifugation at 500 x g for 10 min and stored at ‑20˚C for
future analysis by PCR amplicon sequencing.
Capturing and retrieval of CTCs in clinical blood samples.
An aliquot of 4 ml of blood sample was used to capture
or retrieve CTCs using the Celsee PREP100 instrument
(Celsee Diagnostics) following the protocol provided by the
manufacturer. CTCs were monitored using an inverted fluorescence microscope. CTC enumeration following antibody
labeling was performed manually. PanCK+/CD45‑ nucleated
cells were identified as CTCs. Positive and negative controls
for antibody performance and staining were included in each
experiment. After removal of CD45‑positive cells and enrichment of the spiked‑in CTCs as aforementioned, cells enriched
in the microfluidic chip were retrieved in 2 ml PBS using the
Celsee PREP100 instrument (Celsee Diagnostics) following
the manufacturer's protocol. These cells were then collected
by centrifugation at 500 x g for 10 min and stored at ‑20˚C for
future analysis by PCR amplicon sequencing.
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Table I. Primer sequences used for amplification of fragments containing mutations of interest.
Mutation
Forward outer primer
Reverse outer primer
Forward inner primer
Reverse inner primer

p.K139fs*3

p.T877A

CTGAGTGACAGAGCAAGACCCTAT
AGTGTTTCTGTCATCCAAATACTCC
GTTTCTTTGCTGCCGTCTTC
ACACGCAAATTTCCTTCCAC

AAAATCAGAGGTTGGGGAAGA
ACAACTTGACACTGGGCCATA
CACCTCCTTGTCAACCCTGT
TGGGAAGCAAAGTCTGAAGG

Table II. Primer sequences used for amplification of fragments
containing mutations of interest in clinical blood samples.
Mutation
Forward outer primer
Reverse outer primer
Forward inner primer
Reverse inner primer
Forward inner primer
Reverse inner primer

p.T877A
AAAATCAGAGGTTGGGGAAGA
ACAACTTGACACTGGGCCATA
CACCTCCTTGTCAACCCTGT
TGGGAAGCAAAGTCTGAAGG
AGATTGCGAGAGAGCTGCAT
TGCCATGGGAGGGTTAGATA

PCR amplicon sequencing. Mutations p.K139fs*3 of TP53
in PC3 and p.T877A of AR in LNCaP cells have been previously reported (15,16). To detect these mutations, nested PCR
was employed. Tables I and II lists outer and inner primer
sets designed to amplify each of the mutations. The retrieved
cells were resuspended in 5 µl ddH2O and incubated at 4˚C
for 10 min, and used as the template for PCR amplification.
The PCR assay was set up in a 20‑µl reaction containing 10 µl
KAPA HiFi HotStart Ready Mix (Kapa Biosystems, Inc.,
Wilmington, MA, USA), 300 nM of each outer primer and 1 µl
dimethyl sulfoxide (DMSO) at the following cycling conditions: 2 min at 95˚C, followed in turn by 3 cycles of 20 sec
at 98˚C, 20 sec at 64˚C and 30 sec at 72˚C, 3 cycles of 20 sec
at 98˚C, 20 sec at 61˚C and 30 sec at 72˚C, 3 cycles of 20 sec at
98˚C, 20 sec at 58˚C and 30 sec at 72˚C, 35 cycles of 20 sec at
98˚C, 20 sec at 57˚C and 30 sec at 72˚C and 10 min at 72˚C.
One microliter of amplified PCR products with the outer
primer set was used as the template for the PCR reaction using
the inner primer set under the same conditions. The final PCR
products were examined on 1% agarose gel and subjected to
Sanger sequencing using the inner primers after purification.
Results
Mutation detection in PC3 and LNCaP cell lines. PC3 and
LNCaP cell lines are established prostate cancer cells and have
been widely used in studies on prostate cancer. It has been
reported that PC3 cells possess a deletion in the TP53 gene,
p.K139fs*3 and LNCaP possess a missense A to G mutation in
the AR gene, p.T887A mutation (15,16). To detect these mutations, we designed primers (Table I) targeting the mutations,
performed nested PCR and subsequently sequenced the amplicons by Sanger sequencing. To detect the p.T877A mutation

Figure 1. Nested PCR amplification of the TP53 gene from PC3 cells and the
androgen receptor gene from LNCaP cells. (A) Electrophoresis gel imaging
of nested PCR amplicons from 0, 28, 280, 400, 800 and 1,200 PC3 cells.
(B) Electrophoresis gel imaging of nested PCR amplicons from 0, 5, 10, 20,
25, 100 and 200 LNCaP cells.

of the AR gene in the blood samples of patients, a second
set of inner primers were used to improve the sensitivity of
the assay (Table II). Fig. 1 reveals the PCR products and
Fig. 2 reveals the Sanger sequencing results. The p.K139fs*3
and p.T887A mutations were successfully detected from
28‑1,200 PC3 cells, and 10‑200 LNCaP cells, respectively.
Cell retrieval efficiency using Celsee PREP100. We next
tested CTC enrichment efficiency of the Celsee PREP100
by inputting a total of 110, 220, 330, 440, 550, 880 and 1,100
PC3 cells, and 60, 300, 600, 900, 1,200 and 1,500 LNCaP
cells, respectively. The results are shown in Table III. Overall,
the efficiency for cell retrieval was ~70% with a range from
40 to 121% for PC3 and LNCaP cells. The observation that
some of the cell recovery rates were >100% was due to the
variation of cell counts by hemocytometer at low cell numbers.
CTC enrichment and retrieval efficiencies using spiked‑in
cells in normal donor blood samples. To test the enrichment and retrieval efficiencies of CTC in blood samples, we
spiked PC3 and LNCaP into 4 ml of whole blood samples
from healthy donors and stained the enriched cells for cytokeratins, CD45 and nuclei. Fig. 3 reveals typical images of
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Figure 2. Sanger sequencing results of the nested PCR amplicons from PC3 and LNCaP cells. (A) Sequencing results of TP53 from control gDNA (upper panel)
and PC3 cells (lower panel), revealing a deletion in TP53 from PC3 cells. (B) Sequencing results of AR from control gDNA (upper panel) and LNCaP cells
(lower panel), revealing a missense mutation in AR from LNCaP cells.

Figure 3. Representative images of the enriched cells using Celsee PREP100. Green, red and blue signals indicate cytokeratins and DAPI‑positive, CD45‑negative
and nuclei, respectively. (A) Images from individual channels. (B) Composite images from all 3 channels revealing differential staining of CTCs (green) and
leukocytes (red). It also revealed that circulating tumor cells (CTCs) are captured as a single cell, double cells and cell clusters.
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Table III. Efficiency of CTC retrieval using Celsee PREP100.
Total input PC3 (no. of cells)
Retrieved PC3 (no. of cells)
Recovery rate (%)
Total input LNCaP (no. of cells)
Retrieved LNCaP (no. of cells)
Recovery rate (%)

110
128
116
60
58
96

220
150
68
300
250
83

330
208
63
600
618
103

440
531
121
900
605
67

550
360
65
1,200
1,233
103

880
368
42
1,200
810
68

1,100
750
68
1,500
600
40

CTCs, circulating tumor cells.

Table IV. Efficiency of CTC enrichment from blood samples
using Celsee PREP100.
Cell types
No. of spiked‑in CTC
No. of total captured cells
No. of captured CTC cells
No. of background cells
CTC recovery rate (%)
CTCs vs. background cells (ratio)

PC3

LNCaP

250
240
96
144
38
1:1.50

50
146
37
109
74
1:2.90

CTCs, circulating tumor cells.

the enriched cells in the microfluidic chip, where cytokeratins
and DAPI‑positive (green and blue) and CD45‑negative cells
were considered as CTC cells. The results (Table IV) reveals
that ~40% of 250 spiked‑in PC3 cells and 74% of 50 spiked‑in
LNCaP cells were retrieved after enrichment. Furthermore,
the enriched PC3 and LNCaP cells accounted for ~40 and
25% of the total retrieved cells and the ratio of captured CTCs
to the background cells reached 1:1.5 for PC3 and 1:2.9 for
LNCaP cells, suggesting that the removal of blood cells by
the Celsee PREP100 was nearly complete and the level of
remaining leukocytes in the enriched sample was very low.
CTC enrichment and retrieval using clinical blood samples.
To test the enrichment and retrieval efficiencies of CTC the
blood samples of patients, we stained the enriched cells for
cytokeratins, CD45 and nuclei. Fig. 3 reveals typical images of
the enriched cells in the microfluidic chip, where cytokeratins
and DAPI‑positive (green and blue) and CD45‑negative cells
were considered as CTC cells. For the patient samples that had
CTCs, we processed another 4 ml of the blood samples and
retrieved CTCs for subsequent mutation analysis.
Mutation analysis. In order to test whether or not the mutations p.K139fs*3 of TP53 in PC3 and p.T877A of AR in
LNCaP cells could be detected in the enriched cells from
blood samples, we spiked 50, 100, 300 and 1,000 PC3 cells,
and 25, 50, 100 and 250 LNCaP cells into 4 ml of blood
samples, depleted CD45‑positive cells, enriched and retrieved
the cancer cells using Celsee PREP100. The cells were then

Figure 4. PCR products of the TP53 gene from the enriched PC3 cells from
blood and the androgen receptor gene from enriched LNCaP cells from
blood. (A) Electrophoresis gel imaging of nested PCR amplicons of the
enriched cells from blood samples with spiked‑in 50, 200, 300, 1,000 PC3
cells. (B) Electrophoresis of nested PCR amplicons of the enriched cells from
blood samples with spiked‑in 25, 50, 100 and 250 LNCaP cells.

spun down, resuspended in water and used as templates for
PCR amplification and subsequent Sanger sequencing. Fig. 4
reveals the PCR products. Fig. 5 shows the Sanger sequencing
results of the PCR amplicons, indicating that both mutations
could be successfully detected in the enriched cells. For the
CTCs retrieved from 14 clinical blood samples, we successfully performed the mutation analysis of p.T877A. The AR
mutation (heterozygous mutation) was identified in the
1 sample (CTC 37) tested (Fig. 6) and all other samples were
negative for this mutation. Sixty‑three CTCs were identified in
sample CTC 37.
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Figure 5. Sanger sequencing results of PCR amplicons of the TP53 and androgen receptor genes of the enriched PC3 and LNCaP cells from blood. (A) The
upper panel is the sequencing result from the control gDNA and the lower panel is the representative sequencing result of nested PCR amplicons of the enriched
PC3 cells. (B) The representative Sanger sequencing result of nested PCR amplicons of the enriched LNCaP cells. Arrows indicate the mutations.

Figure 6. Sanger sequencing results of PCR amplicons of the androgen receptor gene of the enriched patient blood samples. The panel is the representative
sequencing result of nested PCR amplicons of the patient blood samples (CTC 31 to CTC 41). Sample (CTC 37) carries a heterozygous AR mutation in its
circulating tumor cells (CTCs).
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Discussion
Molecular characterization of CTCs has been hindered by
low sensitivity and a high level of background leukocytes
of currently available CTC enrichment technologies. We
demonstrated that CTCs can be readily captured and further
characterized with molecular markers using a simple device,
Celsee PREP100. The protocol we report in the present
study enriches and retrieves CTCs from blood samples based
on the fact that tumor cells are larger and less deformable
than normal blood cells. To evaluate the performance on
cell enrichment and retrieval, we prepared prostate cancer
cell lines PC3 and LNCaP and analyzed the captured cells
by PCR amplicon sequencing. We were able to recover an
average of 79% (ranging from 40 to 100%) of 110‑1,100 PC3
cells, and 60‑1,500 LNCaP cells and detect the p.K139fs*3
deletion of TP53 in PC3 cells and the p.T877A mutation
of AR in LNCaP cells. We also tested these two types of
cells spiked into normal donor blood samples, captured and
retrieved the cells and analyzed the retrieved cells by PCR
amplicon sequencing. We were able to capture ~40% of PC3
cells and 74% of LNCaP cells with the ratio of captured
CTCs to the background leukocytes reaching 1:1.5 for PC3
and 1:2.9 for LNCaP cells. The p.K139fs*3 deletion and the
p.T877A mutation were detected in the captured spiked‑in
PC3 and LNCaP cells, respectively. The method was also
tested successfully in clinical blood samples from patients
with metastatic prostate cancer. Our results demonstrated
the potential of CTC molecular characterization for the
diagnosis, prognosis and treatment selection of patients with
metastatic malignancy.
The unique design of the microf luidic chip and
Celsee PREP100 allows separation of CTCs from the background leukocytes and retrieval of the captured CTCs in a
simple fashion. The variability observed on the recovery rate
of cell retrieval is mainly due to the nature of the manual
operation of the protocol. For example, the pressure and speed
of manual pausing and pumping to retrieve the captured cells
could vary from experiment to experiment and operator to
operator. The variable number of background leukocytes could
come from different healthy donors of the blood samples. To
improve the purity of captured cells and the consistency of
the protocol performance, we are developing an automated
pump that can be connected to the Celsee PREP100 to
retrieve captured cells from the microfluidic chip for PCR and
sequencing analyses.
Enrichment of circulating cells can enable a number of
downstream molecular applications. In addition to Sanger
sequencing analysis used in our study, RT‑PCR and DNA array
assays on gene expression profiling, as well as NGS analysis on
several DNA and RNA based genomic applications have been
explored with enriched CTCs. Fluorescence in situ hybridization (FISH) assay on CTCs has also been demonstrated for
determining gene amplification and aberrant copy number
changes in cancer cells. Molecular profiling of CTCs could
produce insightful information towards understanding the
heterogeneity and the complexity of cancer and shed further
light on the mechanisms of tumor metastasis, thus delineating
tumor cells that are relevant to prognosis and therapy choice.
With improvements on automation and standardization,
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enrichment and characterization of CTCs could overcome the
technical limitations of low sensitivity and high background
leukocytes and become a routine diagnostic tool in clinical
use.
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